1. "Department of Pathology and Laboratory Medicine"
Formats
  1. Journal Article (6438)
  2. Meeting Abstract (5172)
  3. Review (332)
  4. Book Section (310)
  5. Editorial (92)
  6. Research Letter (73)
  7. Guidelines (52)
  8. Correspondence (47)
  9. Conference Paper (38)
  10. Miscellaneous (37)
  11. Book Whole (24)
Groups
  1. Department of Pathology and Laboratory Medicine (12615)
  2. GSK Faculty (4773)
  3. Department of Medicine (4722)
  4. Surgery (3639)
  5. Solid Tumor Oncology Division (3422)
  6. Human Oncology and Pathogenesis Program (3037)

More Groups

People
  1. Marc Ladanyi (1327)
  2. Victor Reuter (1228)
  3. Cristina Antonescu (895)
  4. Michael Berger (765)
  5. William Travis (743)
  6. Jinru Shia (719)

More People

Years
  1. 2025 (307)
  2. 2024 (719)
  3. 2023 (766)
  4. 2022 (841)
  5. 2021 (677)
  6. 2020 (787)

More Years

Publications
  1. Laboratory Investigation (1448)
  2. Modern Pathology (1440)
  3. Journal of Clinical Oncology (863)
  4. American Journal of Surgical Pathology (429)
  5. Cancer Research (426)
  6. Blood (349)

More Publications

Publishers
  1. Nature Publishing Group (1939)
  2. Nature Research (1457)
  3. Elsevier Inc. (1139)
  4. American Society of Clinical Oncology (955)
  5. American Association for Cancer Research (923)
  6. Lippincott Williams & Wilkins (896)

More Publishers

Results (12615)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Updated survival and response analyses from a phase 1 study of ivosidenib or enasidenib combined with induction and consolidation chemotherapy in patients with newly diagnosed AML with an IDH1 or IDH2 mutation
    Meeting Abstract

    Stein, E. M.; DiNardo, C. D.; Fathi, A. T.; Mims, A. S.; Savona, M. R.; Stein, A. S.; Stone, R. M.; Winer, E. S.; Seet, C. S.; Döhner, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Expert curation of somatic FLT3 variants by the ClinGen somatic hematologic cancer taskforce (ClinGen HCT)
    Meeting Abstract

    Shao, X.; Rao, S.; Mani, C.; Saliba, J.; He, R.; Kesserwan, C.; Danos, A.; Sheta, L.; Terraf, P.; Raca, G.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Favorable outcomes of patients with limited-stage ocular adnexal DLBCL treated in the rituximab era: Long-term follow-up of a single center experience
    Meeting Abstract

    Qualls, D.; Batlevi, C. L.; Caron, P. C.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; Joffe, E.; Khan, N.; Kumar, A.; Matasar, M. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • A new role for the SRC family member HCK as a driver of BCR/SYK signaling in MYD88 mutated lymphomas
    Meeting Abstract

    Munshi, M.; Liu, X.; Kofides, A.; Tsakmaklis, N.; Demos, M. G.; Guerrera, M. L.; Hunter, Z. R.; Palomba, M. L.; Argyropoulos, K. V.; Patterson, C. J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Molecular evolution of classical Hodgkin lymphoma revealed though whole genome sequencing of Hodgkin and Reed-Sternberg cells
    Meeting Abstract

    Maura, F.; Imielinski, M.; Xiang, J. Z.; Binder, B.; Eng, K.; Uppal, M.; He, F.; Zhang, W.; Gao, Q.; Park, S. I.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Genomic and immune signatures predict sustained MRD negativity in newly diagnosed multiple myeloma patients treated with daratumumab, carfilzomib, lenalidomide, and dexamethasone (D-KRd)
    Meeting Abstract

    Maura, F.; Boyle, E. M.; Diamond, B.; Blaney, P.; Ghamlouch, H.; Ziccheddu, B.; Wang, Y.; Maclachlan, K. H.; Hoffman, J. E.; Hassoun, H.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase I first-in-class trial of MCARH109, a G protein coupled receptor class C group 5 member D (GPRC5D) targeted CAR T cell therapy in patients with relapsed or refractory multiple myeloma
    Meeting Abstract

    Mailankody, S.; Diamonte, C.; Fitzgerald, L.; Kane, P.; Wang, X.; Sikder, D. S.; Senechal, B.; Bermudez, V. P.; Frias, D.; Morgan, J.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The genomic landscape of Waldenström Macroglobulinemia reveals sustained germinal center activity and late-developing copy number aberrations
    Meeting Abstract

    Maclachlan, K. H.; Bagratuni, T.; Kastritis, E.; Ziccheddu, B.; Lu, S. X.; Yellapantula, V. D.; Famulare, C.; Diamond, B.; Chojnacka, M.; Raj, A.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • The BMP/SMAD pathway is a key mediator of leukemic transformation of TP53-mutant post-MPN AML
    Meeting Abstract

    Li, B.; An, W.; Wang, H.; Krishnan, A.; Mowla, S.; Baslan, T.; Koche, R.; Xiao, W.; Lowe, S.; Levine, R. L.; more...
    Blood (2021)

    Fulltext@MSK | Save